Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.42 |
| ▸ | GCGR | P47871 | 2/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9081966 | 0.79 | GABRA2 (0.35) | MAPK14MAPK13MAPK12MAPK11GABRA2 | |
| SCHEMBL7090577 | 0.78 | MAPK14 (0.35) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7088083 | 0.73 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL9277485 | 0.72 | MAPT (0.37) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7090794 | 0.71 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7085315 | 0.69 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7090574 | 0.69 | ALOX5 (0.37) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7084889 | 0.68 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7084428 | 0.68 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL9006002 | 0.62 | HMGCR (0.41) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | MAPK14 1523/4885MAPK13 2251/4885MAPK12 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.